Azithromycin reduces spontaneous and induced inflammation in ΔF508 cystic fibrosis mice

被引:84
作者
Legssyer, Rachida
Huaux, Francois
Lebacq, Jean
Delos, Monique
Marbaix, Etienne
Lebecque, Patrick
Lison, Dominique
Scholte, Bob J.
Wallemacq, Pierre
Leal, Teresinha
机构
[1] Catholic Univ Louvain, B-1200 Brussels, Belgium
[2] Louvain Univ Hosp Mont Godinne, Yvoir, Belgium
[3] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
关键词
D O I
10.1186/1465-9921-7-134
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Inflammation plays a critical role in lung disease development and progression in cystic fibrosis. Azithromycin is used for the treatment of cystic fibrosis lung disease, although its mechanisms of action are poorly understood. We tested the hypothesis that azithromycin modulates lung inflammation in cystic fibrosis mice. Methods: We monitored cellular and molecular inflammatory markers in lungs of cystic fibrosis mutant mice homozygous for the Delta F508 mutation and their littermate controls, either in baseline conditions or after induction of acute inflammation by intratracheal instillation of lipopolysaccharide from Pseudomonas aeruginosa, which would be independent of interactions of bacteria with epithelial cells. The effect of azithromycin pretreatment (10 mg/kg/day) given by oral administration for 4 weeks was evaluated. Results: In naive cystic fibrosis mice, a spontaneous lung inflammation was observed, characterized by macrophage and neutrophil infiltration, and increased intra-luminal content of the proinflammatory cytokine macrophage inflammatory protein-2. After induced inflammation, cystic fibrosis mice combined exaggerated cellular infiltration and lower anti-inflammatory interleukin-10 production. In cystic fibrosis mice, azithromycin attenuated cellular infiltration in both baseline and induced inflammatory condition, and inhibited cytokine (tumor necrosis factor-alpha and macrophage inflammatory protein-2) release in lipopolysaccharide-induced inflammation. Conclusion: Our findings further support the concept that inflammatory responses are upregulated in cystic fibrosis. Azithromycin reduces some lung inflammation outcome measures in cystic fibrosis mice. We postulate that some of the benefits of azithromycin treatment in cystic fibrosis patients are due to modulation of lung inflammation.
引用
收藏
页数:13
相关论文
共 83 条
  • [1] Lower airway inflammation in infants with cystic fibrosis detected by newborn screening
    Armstrong, DS
    Hook, SM
    Jamsen, KM
    Nixon, GM
    Carzino, R
    Carlin, JB
    Robertson, CF
    Grimwood, K
    [J]. PEDIATRIC PULMONOLOGY, 2005, 40 (06) : 500 - 510
  • [2] LOWER RESPIRATORY-INFECTION AND INFLAMMATION IN INFANTS WITH NEWLY-DIAGNOSED CYSTIC-FIBROSIS
    ARMSTRONG, DS
    GRIMWOOD, K
    CARZINO, R
    CARLIN, JB
    OLINSKY, A
    PHELAN, PD
    [J]. BRITISH MEDICAL JOURNAL, 1995, 310 (6994) : 1571 - 1572
  • [3] Interleukin-9 reduces lung fibrosis and type 2 immune polarization induced by silica particles in a murine model
    Arras, M
    Huaux, F
    Vink, A
    Delos, M
    Coutelier, JP
    Many, MC
    Barbarin, V
    Renauld, JC
    Lison, D
    [J]. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2001, 24 (04) : 368 - 375
  • [4] THE RELATIONSHIP BETWEEN INFECTION AND INFLAMMATION IN THE EARLY STAGES OF LUNG-DISEASE FROM CYSTIC-FIBROSIS
    BALOUGH, K
    MCCUBBIN, M
    WEINBERGER, M
    SMITS, W
    AHRENS, R
    FICK, R
    [J]. PEDIATRIC PULMONOLOGY, 1995, 20 (02) : 63 - 70
  • [5] Effect of Macrolides on In vivo ion transport across cystic fibrosis nasal epithelium
    Barker, PM
    Gillie, DJ
    Schechter, MS
    Rubin, BK
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (08) : 868 - 871
  • [6] Mechanisms of disease - Nuclear factor-kappa b - A pivotal transcription factor in chronic inflammatory diseases
    Barnes, PJ
    Larin, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (15) : 1066 - 1071
  • [7] Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis
    Beringer, P
    Huynh, KMT
    Krengkauykiat, J
    Bi, L
    Hoem, N
    Louie, S
    Han, E
    Nguyen, T
    Hsu, D
    Rao, PA
    Shapiro, B
    Gill, M
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (12) : 5013 - 5017
  • [8] Altered respiratory epithelial cell cytokine production in cystic fibrosis
    Bonfield, TL
    Konstan, MW
    Berger, M
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1999, 104 (01) : 72 - 78
  • [9] INFLAMMATORY CYTOKINES IN CYSTIC-FIBROSIS LUNGS
    BONFIELD, TL
    PANUSKA, JR
    KONSTAN, MW
    HILLIARD, KA
    HILLIARD, JB
    GHNAIM, H
    BERGER, M
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1995, 152 (06) : 2111 - 2118
  • [10] NORMAL BRONCHIAL EPITHELIAL-CELLS CONSTITUTIVELY PRODUCE THE ANTIINFLAMMATORY CYTOKINE INTERLEUKIN-10, WHICH IS DOWN-REGULATED IN CYSTIC-FIBROSIS
    BONFIELD, TL
    KONSTAN, MW
    BURFEIND, P
    PANUSKA, JR
    HILLIARD, JB
    BERGER, M
    [J]. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1995, 13 (03) : 257 - 261